Concepedia

Anna Kondic

AK

9

Publications

850

Citations

9

H-Index

2014

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of California, Los Angeles

Quantitative BioSciences

Anna Kondic is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and oncology.

Top concepts

Publications per year

2014–2022

9

Publications

9

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

David C. Turner, Anna Kondic, Keaven M. Anderson et al. · Clinical Cancer Research · 2018 · 205 citations

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee, David C. Turner, Enriqueta Felip et al. · Annals of Oncology · 2016 · 158 citations · Full text

, , +6

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors

Malidi Ahamadi, Tomoko Freshwater, Marita Prohn et al. · CPT Pharmacometrics & Systems Pharmacology · 2016 · 147 citations · Full text

, , +18

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Hongshan Li, Jingyu Yu, Chao Liu et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2017 · 135 citations

, , +8

A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model

K. Melissa Hallow, Arthur Lo, Jeni Beh et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 2014 · 76 citations

, , +15

Rows per page

1–5 of 9